1 day ago · Background: The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs placebo (PBO) + ENZA as 1L treatment in pts with mCRPC unselected for homologous recombination repair (HRR) gene alterations (all-comers; cohort 1). Here we report final OS data, a descriptive update of rPFS, and extended safety follow-up in cohort 1.

4 days ago · Adding 177 Lu-PSMA-617 to enzalutamide improves survival and quality of life in patients with metastatic castration-resistant prostate cancer (mCRPC) who are at risk of early treatment failure on ...

1 day ago · Background: Resistance to androgen receptor (AR) pathway inhibitors (ARPI; e.g., abiraterone, enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) may be driven by preservation of AR signaling through various mechanisms. Enhancer of zeste homolog 2 (EZH2) is implicated in the pathogenesis of prostate cancer and ARPI resistance. Combining ARPI with therapies that modulate ...

1 day ago · Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 …

In the randomized phase III AFFIRM study, significant improvements in survival versus placebo were observed when enzalutamide was used as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) following prior treatment with docetaxel.

Jul 22, 2023 · We aimed to compare the efficacy and safety of talazoparib (a PARP inhibitor) plus enzalutamide (an androgen receptor blocker) versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Oct 17, 2022 · We aimed to evaluate the efficacy of continuing enzalutamide after progression in controlling metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel and prednisolone.

Enzalutamide (ENZA) and Lutetium-177-prostate-specific membrane antigen-617 (LuPSMA) both improve overall survival (OS) in mCRPC. Preclinical and clinical data suggest synergy for LuPSMA with androgen receptor pathway inhibitors (ARPI) in mCRPC.

The U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

6 days ago · Adding [177 Lu]Lu-PSMA-617 (LuPSMA; Pluvicto) to enzalutamide (Xtandi) significantly improved overall survival (OS) and quality of life (QOL) in patients with metastatic castration-resistant prostate cancer (mCRPC) at high risk for early treatment failure on enzalutamide, according to results from the phase 2 ENZA-p trial shared at the 2025 ...